Calcitriol in the Treatment of Immunoglobulin A (IgA) Nephropathy
Status:
Completed
Trial end date:
2007-09-01
Target enrollment:
Participant gender:
Summary
Immunoglobulin A (IgA) nephropathy is the most common type of primary glomerulonephritis in
the world. A wealth of literature suggests that vitamin D and its analogs have profound
effects on immune system function and glomerular mesangial cell proliferation. Calcitriol, an
active form of vitamin D, is commonly used for the treatment of secondary hyperparathyroidism
in patients with advanced chronic kidney diseases. Therefore, the investigators plan to
conduct a open-label single-arm study to evaluate the safety and efficacy of calcitriol in
the treatment of IgA nephropathy. Ten patients with biopsy-proven IgA nephropathy and
persistent proteinuria despite conventional therapy will be recruited. They will be treated
with calcitriol for 12 weeks. Proteinuria, renal function, serum and urinary inflammatory
markers will be monitored. This study will explore the potential anti-proteinuric and
anti-inflammatory effects of calcitriol in the treatment of IgA nephropathy, which is a major
cause of dialysis-dependent renal failure.
Phase:
Phase 4
Details
Lead Sponsor:
Chinese University of Hong Kong
Treatments:
Antibodies Calcitriol Immunoglobulin A Immunoglobulins